Malaysia Pharmaceuticals & Healthcare Report Q1 2015
Headline Expenditure Projections
Risk/Reward Index : Malaysia's Pharmaceutical Risk/Reward Index (RRI) score for Q115 is 58.9 out of 100, making it the eighth most attractive pharmaceutical market in the Asia Pacific region. It posts above-average scores for every indicator.
- Pharmaceuticals: MYR6.60bn (USD2.10bn) in 2013 to MYR7.22bn (USD2.25bn) in 2014; +9.3 % in local currency and +7.6% in US dollar terms. Forecast revised down from last quarter to better suit current market conditions.
- Healthcare: MYR40.27bn (USD12.78bn) in 2013 to MYR43.79bn (USD13.68bn) in 2014; +8.7% in local currency and +7.1% in US dollar terms. Forecast unchanged from last quarter's figures.
Key Trends And Developments
In November 2014, Health Minister Dr Subramaniam stated that Malaysia attracted over 770,000 foreigners seeking healthcare at the country's private hospitals in 2013, with Indonesians accounting for around 56.76% of the total. The number of Indonesians travelling for healthcare to Malaysia stood at over 437,000: more than 27,000 Indians, about 22,300 Japanese and 21,000 Chinese people. The country also recorded health tourism from other nations, including Libya (about 19,000), Britain (17,000), Australia (13,300), the US (12,300), Bangladesh (about 12,000) and the Philippines (10,500). About 95 foreign medical specialists, including 18 female specialists, were practicing in Malaysia as of the end of September 2014.
The Malaysia Pharmaceuticals & Healthcare Report features Business Monitor International (BMI)''s forecasts for drugs and healthcare expenditure and imports and exports, focusing on the growth outlook for the prescription, OTC, patented drugs and generics market segments.
BMI''s Malaysia Pharmaceuticals & Healthcare Report provides industry professionals, strategists, company executives, investors, analysts and sales/marketing heads with independent forecasts and competitive intelligence on the Malaysian pharmaceutical and healthcare industry.
- Benchmark BMI''s independent pharmaceutical and healthcare industry forecasts for Malaysia to test other views - a key input for successful budgeting and strategic business planning in the Malaysian pharmaceutical and healthcare market.
- Target business opportunities and risks in the Malaysian pharmaceutical and healthcare sector through our reviews of latest industry trends, regulatory changes and major deals, projects and investments in Malaysia.
- Assess the activities, strategy and market position of your competitors, partners and clients via our Company Profiles (inc. SWOTs, KPIs and latest activity) and Competitive Landscape Tables.
BMI Industry View & Industry SWOT
An at-a-glance perspective on latest regulatory developments, key forecast indicators and major corporate developments, covering the prescription, OTC and generics markets. The SWOT outlines strategic factors which affect BMI''s forecast analysis, and taken together with BMI''s political, economic and business environment SWOTS, it gives a complete overview of market climate.
Snapshot of key market characteristics, including total size of pharmaceuticals and healthcare segments, growth drivers, leading therapeutic areas and the competitive landscape.
Details of the industry regulatory framework and key legislation covering the licensing of new products/services, pricing and reimbursements, intellectual property, taxation and advertising, as well as an analysis of the overall regulatory burden.
Focus on government healthcare reforms, epidemiological trends, company M&As, product launches, market entries, FDI activity, R&D, biotechnology, clinical trials and supply chain issues.
BMI Industry Forecasts
Forecasts to end-2018 for all key industry indicators (see list below) supported by explicit assumptions, plus analysis of key downside risks to the main forecast, including:
Healthcare: Total healthcare expenditure (US$bn), healthcare expenditure (% of GDP), healthcare expenditure per capita (US$), hospital beds (per `000 population), doctors (per `000 population), birth and mortality rate (per `000 population)
Pharmaceutical market: Drug expenditure (US$bn), drug expenditure (% of GDP), drug expenditure per capita (US$)
Patented drug market: Prescription drug sales (US$bn), prescription sales (% of total sales), sales broken down by 14 therapeutic areas (cardiovascular, anti-infectives etc.)
Generic drug market: Generic product sales (US$bn), generic sales (% of total sales)
OTC drug market: OTC sales (US$bn), OTC sales (% of total sales), sales broken down by product types (analgesics, skin treatments, vitamins and minerals etc.)
Medical Devices: Medical device sales (US$bn), medical device sales (% of total healthcare market)
Macroeconomic Forecasts: Nominal and real GDP, % real GDP growth, % private consumption growth, % industrial output growth, % consumer price index, % GDP price deflator, exports, imports, trade balance, current account balance, foreign direct investment, exchange rate against US$, government expenditure, external debt.
The competitive landscape section provides comparative company analyses and rankings by US$ sales and % share of total sales - for the total pharmaceutical sector, as well as the OTC, generics, and distribution sub-sectors.
Examines the competitive positioning and short- to medium-term business strategies of key industry players. Strategy is examined within the context of BMI''s industry forecasts, our macroeconomic views and our understanding of the wider competitive landscape to generate Company SWOT analyses. The latest financial and operating statistics and key company developments are also incorporated within the company profiles, enabling a full evaluation of recent company performance and future growth prospects.
Malaysia's 2015 budget reinforces our upbeat outlook on the country's pharmaceutical market. Rising healthcare expenditure plans to improve medical access and efforts to mitigate the impact of the Goods and Service Tax on medicine prices will provide companies with significant revenue - earn ing opportunities. However, downside risks to our outlook include further economic slowdown forecast for 2015, worries of an increasing number of imitation drugs and growing political differences within both the o pposition and ruling coalitions.
BMI Industry View
Pharmaceutical Market Forecast
Table: Pharmaceutical Sales, Historical Data And Forecasts (Malaysia 2010-2018)
Healthcare Market Forecast
Table: Healthcare Expenditure Trends, Historical Data And Forecasts (Malaysia 2010-2018)
Table: Government Healthcare Expenditure Trends, Historical Data And Forecasts (Malaysia 2010-2018)
Table: Private Healthcare Expenditure Trends, Historical Data And Forecasts (Malaysia 2010-2018)
Prescription Drug Market Forecast
Table: Prescription Drug Market Indicators, Historical Data And Forecasts (Malaysia 2010-2018)
Patented Drug Market Forecast
Table: Patented Drug Market Indicators, Historical Data And Forecasts (Malaysia 2010-2018)
Generic Drug Market Forecast
Table: Generic Drug Market Indicators, Historical Data And Forecasts (Malaysia 2010-2018)
OTC Medicine Market Forecast
Table: Over-The-Counter (OTC) Medicine Market Indicators, Historical Data And Forecasts (Malaysia 2010-2018)
Pharmaceutical Trade Forecast
Table: Pharmaceutical Trade Data And Forecasts (Malaysia 2012-2018)
Table: Pharmaceutical Trade Data And Forecasts local currency (Malaysia 2012-2018)
Other Healthcare Data
Key Risks To BMI's Forecast Scenario
Table: Economic Activity (Malaysia 2009-2018)
Industry Risk Reward Ratings
Asia Pacific Risk/Reward Ratings
Malaysia Risk/Reward Ratings
Industry Trends And Developments
Table: 2011 Entry Points Projects Summary
Table: Main Features Of 1Care
Healthcare Sector Developments
Table: Public Sector And Private Sector Healthcare Developments
Research & Development
Table: Drug Applications by Type, 2002-2010
Table: Registered Pharmaceutical Products by Type, 2002-10
Intellectual Property Issues
Table: Leading Malaysian Pharmaceutical And Healthcare Companies
Table: Drug Wholesalers & Importers, 2002-2010
Pharmaceutical Retail Sector
Chemical Company Of Malaysia
Merck & Co
Eli Lilly Malaysia
Table: Malaysia's Population By Age Group, 1990-2020 ('000)
Table: Malaysia's Population By Age Group, 1990-2020 (% of total)
Table: Malaysia's Key Population Ratios, 1990-2020
Table: Malaysia's Rural And Urban Population, 1990-2020
Pharmaceutical Expenditure Forecast Model
Healthcare Expenditure Forecast Model
Notes On Methodology
Risk/Reward Ratings Methodology
Table: Pharmaceutical Risk/Reward Ratings Indicators
This report does not have a list of Companies Mentioned available
This report does not have a press release associated with it